DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20182695

An analgesic to bridge the gap between Narcotics and NSAIDs: opiorphin

Sujatha S., Priyadharshini R., Niloofar Khansari Nejad, Yashoda Devi B. K., Shwetha V., Pavan Kumar T., Rizwana Azmi

Abstract


Pain management is an all-time challenge in dentistry. Discontent to pain management is a concern among patients and professionals. Unrelieved pain affects physical and mental well-being contributing to delayed recovery, psychological distress and anxiety. Studies have revealed that chronic pain interferes with normal daily chores of the individual like exercise, sleep, social life and lifestyle. At one end of pain management spectrum are Non-steroidal anti-inflammatory drugs (NSAIDs) while at the other end are the opioids. These drugs are not without constituent side effects. The quest is for new analgesics with potent and long term analgesia with minimal or no side effects. An analgesic that is intermediate in this spectrum is the need of the hour. Opiorphin is an endogenous peptide isolated from human saliva. Opiorphin produces analgesia, by inhibiting enkephalin (ENK) metabolizing enzymes, thus increasing the half-life of circulating ENKs. Apart from being a potent analgesic it can also be a potential biomarker for various systemic and psychosocial disorders. This review focuses on the pharmacological effects of opiorphin and its potential role as a biomarker in various disease conditions.


Keywords


Analgesics, Enkephalinase inhibitors, Endogenous opioids, Enkephalins, Opiorphin

Full Text:

PDF

References


Williams AC de C, Craig KD. Updating the definition of pain. Pain. 2016;157(11):2420-3.

Bond M. Pain education issues in developing countries and responses to them by the International Association for the Study of Pain. Pain Res Manag. 2011;16(6):404-6.

Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM. Pain and poppies: the good, the bad, and the ugly of opioid analgesics. J Neurosci. 2015;35(41):13879-88.

Wollemann M, Rougeot C. Human Opiorphin an Endogenous Inhibitor of Enkephalin-Inactivating Ectopeptidases that Displays Antinociception: A Review. Curr Bioact Compd. 2016;12(4):230-5.

Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN, et al. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci. 2006;103(47):17979-84.

Bogeas A, Dufour E, Bisson JF, Messaoudi M, Rougeot C. Structure-activity relationship study and function-based peptidomimetic design of human opiorphin with improved bioavailability property and unaltered analgesic activity. Biochem Pharmacol. 2013;2(3):2167-0501.

Rosa M, Arsequell G, Rougeot C, Calle LP, Marcelo F, Pinto M, et al. Structure–Activity Relationship Study of Opiorphin, a Human Dual Ectopeptidase Inhibitor with Antinociceptive Properties. J Med Chem. 2012;55(3):1181-8.

Jutkiewicz EM. RB101-mediated Protection of Endogenous Opioids: Potential Therapeutic Utility? CNS Drug Rev [Internet]. 2007 Jun 1;13(2):192-205.

Poras H, Bonnard E, Dangé E, Fournié-Zaluski MC, Roques BP. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment. J Med Chem. 2014;57(13):5748-63.

Javelot H, Messaoudi M, Garnier S, Rougeot C. Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent δ-opioid pathways. J Physiol Pharmacol. 2010;61(3):355.

Yang QZ, Lu SS, Tian XZ, Yang AM, Ge WW, Chen Q. The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice. Neurosci Lett. 2011;489(2):131-5.

Sitbon P, Van Elstraete A, Hamdi L, Juarez-Perez V, Mazoit JX, Benhamou D, et al. STR-324, a stable analog of opiorphin, causes analgesia in postoperative pain by activating endogenous opioid receptor-dependent pathways. Anesthesiol J Am Soc Anesthesiol. 2016;125(5):1017-29.

Brkljačić L, Sabalić M, Salarić I, Jerić I, Alajbeg I, Nemet I. Development and validation of a liquid chromatography–tandem mass spectrometry method for the quantification of opiorphin in human saliva. J Chromatogr B. 2011;879(32):3920-6.

Dufour E, Villard-Saussine S, Mellon V, Leandri R, Jouannet P, Ungeheuer MN, et al. Opiorphin secretion pattern in healthy volunteers: gender difference and organ specificity. Biochem Anal Biochem. 2013;2(3):2-11.

Tian X, Chen J, Xiong W, He T, Chen Q. Effects and underlying mechanisms of human opiorphin on colonic motility and nociception in mice. Peptides. 2009;30(7):1348-54.

Tian X, Chen Y, Bai L, Luo P, Du X, Chen Q, et al. Effects and underlying mechanisms of human opiorphin on cardiovascular activity in anesthetized rats. Eur J Pharmacol. 2015;749:32-8.

Al Saffar MT, AL Sandook TA, Y Taha M. A Possible New Concept in the Mechanism of Action of Local Anesthesia. Am J Med Biol Res [Internet]. 2013 Nov 22;1(4):134-7. Available at: http://pubs.sciepub.com/ajmbr/1/4/5

Salarić I, Sabalić M, Alajbeg I. Opiorphin in burning mouth syndrome patients: a case-control study. Clin Oral Investig. 2017;21(7):2363-70.

Boucher Y, Braud A, Dufour E, Agbo-Godeau S, Baaroun V, Descroix V, et al. Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study. Clin Oral Investig. 2016.

Mennini N, Mura P, Nativi C, Richichi B, Di Cesare Mannelli L, Ghelardini C. Injectable liposomal formulations of opiorphin as a new therapeutic strategy in pain management. Futur Sci OA. 2015 Nov;1(3).